Johnson & Johnson Reports Earnings Surprise Driven by Strong Sales of Key Products in Q1

[Asia Economy Reporter Eunmo Koo] Johnson & Johnson, a leading company in the U.S. healthcare sector, achieved a surprise performance in the first quarter of this year due to strong sales of its flagship products.

According to Hanwha Investment & Securities on the 18th, Johnson & Johnson's first-quarter sales this year increased by 3.3% compared to the same period last year, reaching $20.69 billion, surpassing the consensus estimate of $19.48 billion. During the same period, non-GAAP net income rose 8.7% to $6.15 billion, exceeding the market expectation of $5.27 billion by 16.8%, and adjusted earnings per share (EPS) grew 9.5% to $2.30, beating the consensus of $2.00 by 15.3%, marking an earnings surprise.

Choi Bowon, a researcher at Hanwha Investment & Securities, stated in a report that although the medical devices segment underperformed due to delays in annual plans caused by the impact of COVID-19, sales of key products such as Tylenol, Zyrtec, Neutrogena, and Aveeno increased, resulting in a 9.2% year-over-year rise in consumer health segment sales. Additionally, strong sales growth of major pharmaceuticals, including Stelara for autoimmune inflammatory diseases and Darzalex for multiple myeloma, led to an 8.7% year-over-year increase in pharmaceutical segment sales, driving overall revenue growth.

Despite presenting conservative guidance, the company is still regarded as highly attractive for long-term investment. Johnson & Johnson lowered its guidance in January due to ongoing legal disputes and uncertainties such as COVID-19. However, researcher Choi analyzed, “Despite the COVID-19 situation, strong sales of key treatments like Stelara and Darzalex, as well as pharmaceuticals such as Tylenol and Zyrtec, continue. As a representative dividend growth company that has increased dividends for 58 consecutive years, its long-term investment appeal remains high.”

Furthermore, Johnson & Johnson announced last month that clinical trials for its COVID-19 vaccine could begin as early as September this year, and during the first-quarter conference call, it announced the possibility of production in the first quarter of 2021. Researcher Choi forecasted, “Since sales of COVID-19 related products are increasing in the consumer health business segment, the company is judged to have relatively limited fundamental damage from COVID-19. Although the medical devices segment is expected to face short-term negative impacts due to delays in executing annual plans caused by COVID-19, growth in the medical devices segment is expected once the COVID-19 situation subsides.”

This content was produced with the assistance of AI translation services.